Navigation Links
Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/7/2013

PARSIPPANY, N.J., May 7, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro , Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Actavis' Investor Relations Web site at http://ir.actavis.com.  The webcast can also be accessed at the following URL:

http://www.veracast.com/webcasts/baml/healthcare2013/id49059650.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

Actavis is the world's third-largest generics prescription drug manufacturer.  Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.   Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. 

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development. 

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually.  Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.CONTACTS:Investors:Lisa DeFrancesco(862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )


'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
2. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
3. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
4. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
5. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
8. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
9. Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
10. Cantel Medical To Present At The Bank Of America Merrill Lynch Health Care Conference
11. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... NEW YORK , January 18, 2017 ... perception of people regarding the use of cannabis both for ... not only are more Americans open to the use of ... and financial sectors. According to Arcview Market Research, the North ... 2016, up 30% from the previous year. The research projects ...
(Date:1/18/2017)... TOKYO , Jan. 18, 2017  Astellas ... , "Astellas" ) today announced its participation in ... access to non-communicable disease (NCD) prevention, diagnostics and ... with 21 other leading pharmaceutical companies and in ... Union for International Cancer Control (UICC), Astellas will ...
(Date:1/17/2017)... LONDON , Jan. 17, 2017 ... health and for the treatment of disease. The ... individual response to a therapy. The approach studies ... with their lifestyle and environment. In January 2015, ... precision medicine to all diseases with more than ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages to prevent distracted ... from Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can ... totaling $15,000 will be awarded for the best peer-to-peer messages sharing solutions to ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Connecticut Dermatology ... H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive ... . , “It is with considerable pleasure to welcome back Dr. Kim to the ...
(Date:1/19/2017)... ... , ... Infinity® Massage Chairs announced today that Dan Grover has joined the ... Grover comes with a total of 15 years experience in consumer goods and an ... President of Direct Sales at Traeger® Wood Pellet Grills. , Grover has elevated ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of ... discussion about the benefits of fidgeting to relieve stress and anxiety. No one ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on ...
(Date:1/18/2017)... ... 18, 2017 , ... The VA Maryland Health Care System ... research project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, PhD, ... the disease without compromising normal immune function that often occurs during autoimmune diseases. ...
Breaking Medicine News(10 mins):